Similar articles

• Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines.

  Dalakas MC. Dalakas MC. Muscle Nerve. 1999 Nov;22(11):1479-97. doi: 10.1002/(sici)1097-4598(199911)22:11<1479::aid-mus3>3.0.co;2-b. Muscle Nerve. 1999. PMID: 10514226 Review.
• Inhibiting leukocyte recruitment to the brain by IVIg: is it relevant to the treatment of demyelinating CNS disorders?

  Dalakas MC. Dalakas MC. Brain. 2004 Dec;127(Pt 12):2569-71. doi: 10.1093/brain/awh343. Brain. 2004. PMID: 15561895 No abstract available.
• [Inflammation and demyelinization: IgIV mode of action].

  Vallat JM, Magy L, Keita M. Vallat JM, et al. Rev Neurol (Paris). 2006 Jun;162 Spec No 1:3S12-3S16. Rev Neurol (Paris). 2006. PMID: 17075522 Review. French.
• A case of acute combined central and peripheral demyelination.

  Thomas AA, Stommel EW. Thomas AA, et al. J Clin Neuromuscul Dis. 2014 Mar;15(3):112-6. doi: 10.1097/CND.0000000000000025. J Clin Neuromuscul Dis. 2014. PMID: 24534834
• Long-term regular plasmapheresis as a maintenance treatment for chronic inflammatory demyelinating polyneuropathy.

  Isose S, Mori M, Misawa S, Shibuya K, Kuwabara S. Isose S, et al. J Peripher Nerv Syst. 2010 Jun;15(2):147-9. doi: 10.1111/j.1529-8027.2010.00263.x. J Peripher Nerv Syst. 2010. PMID: 20626778 No abstract available.